TIDMMPH
RNS Number : 9504O
Mereo BioPharma Group plc
04 June 2020
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH
AFRICA, THE RUSSIAN FEDERATION, THE REPUBLIC OF IRELAND OR JAPAN OR
IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE
PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO
SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION,
INCLUDING THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE RUSSIAN FEDERATION, THE
REPUBLIC OF IRELAND OR JAPAN. NEITHER THIS ANNOUNCEMENT NOR
ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED
UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY
JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER
THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF
THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC
DOMAIN.
Mereo BioPharma Announces Completion of $70 Million Private
Placement
Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease
Product Portfolio
London and Redwood City, Calif., June 4, 2020 - Mereo BioPharma
Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion
of a $70 million (GBP56 million) private placement (the
"Fundraising") with a number of new and existing U.S based
institutional and accredited investors. OrbiMed led the Fundraising
with participants including Vivo Capital, Surveyor Capital (a
Citadel company), Pontifax Venture Capital, Samsara BioCapital,
Commodore Capital, and funds managed by Janus Henderson Investors
alongside existing investors Boxer Capital of Tavistock Group and
Aspire Capital Fund, LLC.
Highlights
-- Private placement completed raising $70.0 million (GBP56.0 million) before expenses.
-- New Ordinary Shares and Convertible Loan Notes issued provide
the Company with certainty of receiving the full amount of the
proceeds of the private placement at closing.
o 89,144,630 new Ordinary Shares have been placed at the Issue
Price to raise $19.4 million (GBP15.5 million) before expenses,
utilising share authorities granted on 2 June 2016 and 19 June 2019
and issued on a non-pre-emptive basis.
o Convertible Loan Notes have been issued in an aggregate
principal amount $50.6 million (GBP40.5 million) to complete the
Fundraising.
-- Price per Placing Share of 17.4 pence.
-- Investors have received conditional Warrants to subscribe for
further Ordinary Shares in an aggregate number equal to 50 per cent
of both the new Ordinary Shares purchased by that investor in the
Placing and the Ordinary Shares issuable upon conversion of the
Convertible Loan Notes purchased by that investor in the
Fundraising, with an exercise price of 34.8 pence per Warrant. The
Warrants will be capable of being exercised for a period of 3 years
after the date on which the Resolutions are passed.
-- SVB Leerink acted as the exclusive placement agent to the
Company in connection with the Fundraising.
Mereo is also announcing today plans to advance etigilimab
(Anti-TIGIT) into a Phase 1b study in Q4 2020 alongside progressing
its rare disease product portfolio. This is based on the Company's
existing promising clinical data with etigilimab as well as the
increasing interest in TIGIT as an immuno-oncology target. The
Company intends to complete a strategic partnership for setrusumab
for the treatment of osteogenesis imperfecta ("OI") prior to
initiation of the pivotal Phase 3 study and to complete the ongoing
Phase 2 study of alvelestat for the treatment of alpha-1
antitrypsin deficiency ("AATD"), with topline data currently
expected in 2H 2021.
Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, said,
"We are delighted to have attracted the support of such a broad
range of high-quality institutional investors. We are pleased to
also be announcing today that we plan to progress etigilimab into a
Phase 1b study and believe etigilimab has the potential to target a
significant unmet need in oncology. We look forward to progressing
etigilimab, setrusumab and alvelestat further and believe this
Fundraising leaves Mereo extremely well placed to progress on our
strategy."
Etigilimab (Anti-TIGIT)
Etigilimab is an antibody against TIGIT (T-cell immunoreceptor
with Ig and ITIM domains). TIGIT is a next generation checkpoint
receptor shown to block T-cell activation and the body's natural
anti-cancer immune response. Etigilimab is an IgG1 monoclonal
antibody which binds to the human TIGIT receptor on immune cells
with a goal of improving the activation and effectiveness of T-cell
and NK cell anti-tumor activity. Mereo completed a Phase 1a dose
escalation clinical trial with etigilimab in patients with advanced
solid tumors and enrolled patients in a Phase 1b study in
combination with nivolumab in selected tumor types.
23 patients were treated in the Phase 1a dose escalation study
with doses up to 20mg/kg Q2W. Tumor types included colorectal
cancer, endometrial cancer, pancreatic cancer and other tumor
types. No dose limiting toxicities were observed. In the Phase 1b
combination study, a total of ten patients, nine of whom had
progressed on prior anti-PD1/PD-L1 therapies were enrolled at doses
of 3, 10, and 20 mg/kg. Eight patients were evaluable for tumor
growth assessment, and all of these patients had progressed on
PD1/PD-L1 therapies with best responses including two patients with
a partial response and stable disease. Patients remained on study
for up to 224 days. No dose limiting toxicities (DLTs) were
observed and the most common related adverse events included
fatigue, rash, and pruritis.
The Company
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for oncology and rare diseases. Mereo's
lead oncology product candidate, etigilimab ("Anti-TIGIT"), has
completed a Phase 1a dose escalation clinical trial in patients
with advanced solid tumors and has been evaluated in a Phase 1b
study in combination with nivolumab in select tumor types. Mereo's
rare disease product portfolio consists of setrusumab, which has
completed a Phase 2b dose-ranging study in adults with osteogenesis
imperfecta ("OI"), as well as alvelestat, which is being
investigated in a Phase 2 proof-of-concept clinical trial in
patients with alpha-1 antitrypsin deficiency ("AATD").
Use of Proceeds
The net proceeds from the Fundraising will be used primarily to
fund clinical development activities of the Company's lead product
candidates and for general corporate purposes. The Company will
utilise $13 million (GBP10.4 million) to reduce current
indebtedness (including interest) of $17.6 million (GBP14.1
million). In the absence of the receipt of any other income, the
Board expects that the resulting net proceeds of the Fundraising
will fund the Company into 2022.
None of the proceeds of the Fundraising will be used to make any
dividend or distribution, or repurchase shares from any
shareholder.
Details of the Fundraising
The Placing comprised the placing of 89,144,630 new Ordinary
Shares at the Issue Price to raise up to approximately $19.4
million (GBP15.5 million) before expenses, utilising the existing
share authorities granted on 2 June 2016 and 19 June 2019, and
issued on a non-pre-emptive basis. Application has been made to the
London Stock Exchange for the Placing Shares to be admitted to
trading on AIM ("Admission"). It is expected that Admission will
become effective at 8.00 a.m. (GMT) on 5 June 2020.
Following the issue of the Placing Shares, the Company's issued
share capital will comprise 213,652,487 Ordinary Shares. The total
number of voting rights in the Company will be 213,652,487. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.
The Company has also issued 40,533,671 Convertible Loan Notes as
part of the Fundraising in an aggregate principal amount of $50.6
million (GBP40.5 million). Subject to the passing of the
Resolutions to be proposed at the General Meeting, the Convertible
Loan Notes will be convertible into a maximum of 232,952,121 new
Ordinary Shares. Immediately following the passing of the
Resolutions, it is expected that that approximately 21,938,321
Convertible Loan Notes will convert automatically into an
additional 126,082,304 Ordinary Shares initially. The Company will
issue and allot those additional new Ordinary Shares and will make
application to the London Stock Exchange for them to be admitted to
trading on AIM.
In the event that the Resolutions are not passed, the
Convertible Loan Notes will not be capable of being converted into
new Ordinary Shares but will remain outstanding, to be repaid by
the Company in accordance with their terms, details of which are
set out below.
Further details of the Convertible Loan Notes are set out
below.
Arrangements with OrbiMed
In recognition of OrbiMed's participation in, and assistance
with, the Fundraising, the Company has agreed to grant OrbiMed
certain rights. OrbiMed will have the right to nominate two persons
to be appointed to the Board of Directors (out of a maximum number
of 9 directors), for a period of 180 days subject to the usual
regulatory compliance.
Related Party Transaction
As at June 1, 2020, Aspire Capital Fund, LLC held approximately
11.5 per cent. of Mereo's issued ordinary share capital and as such
is considered to be a related party of the Company as defined by
the AIM Rules. The participation by Aspire in the Fundraising
therefore constituted a related party pursuant to AIM Rule 13.
The Directors of Mereo, having consulted with the Company's
nominated adviser, Cantor Fitzgerald Europe, consider that the
terms of the participation by Aspire are fair and reasonable
insofar as the shareholders of the Company are concerned.
Details of the Loan Notes
The Loan Notes comprise of three potential tranches:
-- an initial tranche of 40,533,671 Notes representing $50.6
million ( GBP40.5 million) issued to all Investors (the "Tranche 1
Notes" or "Convertible Loan Notes");
-- a second tranche of up to GBP40.0 million representing
approximately 115,034,554 ordinary shares which may be issued
following the third anniversary of the date on which the
Resolutions are passed to certain holders of Tranche 1 Notes in
lieu of the holder exercising its subscription rights under the
Warrants (the "Tranche 2 Notes") and in return for payment by that
holder of the aggregate exercise price of the relevant Warrants;
and
-- a third tranche of up to GBP56.0 million, which may be
issued, if the Resolutions are not passed at the General Meeting
(or at any subsequent general meeting) held on or before 7 August
2020 (the "Tranche 3 Notes").
The Tranche 1 Notes have a maturity date of June 2023 unless
otherwise extended, converted or accelerated. The Tranche 2 Notes
have a maturity date of three years from their date of issue (i.e.
such that they would be anticipated as becoming due in 2026) unless
otherwise extended, converted or accelerated. The Tranche 3 Notes
have a maturity date of August 2025 unless otherwise extended,
converted or accelerated. The Tranche 1 Notes and Tranche 2 Notes
may be extended by certain holders beyond the initial maturity date
to have a longstop maturity date of 10 years from the date of the
Loan Note Instrument.
Tranche 1 Notes will initially bear interest at a fixed rate of
10% per annum, which will be retroactively reduced to a rate of 6%
per annum to the date of issue if the Resolutions are passed on or
before 7 August 2020. If the Tranche 1 Notes are extended, they
cease to bear interest from that extension. Tranche 2 Notes and
Tranche 3 Notes do not accrue interest (unless default interest
applies). Following an event of default by the Company, default
interest will accrue on all Loan Notes at 2% above the applicable
rate in force at that time for the relevant Loan Notes.
All the Loan Notes are unsecured and have been contractually
subordinated to the Company's existing senior debt facility with
Silicon Valley Bank and Kreos Capital pursuant to the terms of a
Subordination Agreement to which all Investors have acceded as part
of the Fundraising.
If the Resolutions are not passed on or before 7 August 2020,
the holders of Tranche 1 Notes are entitled to an additional fee
(the "Uplift Payment"). The Uplift Payment is designed to
compensate the Tranche 1 Noteholders for being unable to
participate in the equity of the Company through the conversion of
the Tranche 1 Notes and the exercise of Warrants. The value of the
Uplift Payment for each Investor shall be equal to the aggregate
principal amount of the Loan Notes held by such investor on 7
August 2020. Any Investor who fails to attend the General Meeting
(in person or by proxy) and vote in favor of the Resolutions shall
not be entitled to the Uplift Payment. Any Uplift Payment if due is
payable on the redemption date of the relevant Notes.
If the Resolutions have not been passed at a time when the
Company undergoes a change of control, each Noteholder on the date
of such change of control, shall (to the exclusion of the Uplift
Payment) be entitled to a payment equal to the amount of
consideration they would have received on such change of control
had the Resolutions been passed and they had received their full
entitlement of Ordinary Shares and all Warrants they held had
become exercisable, less the aggregate principal and interest
outstanding on the Tranche 1 Notes and certain residual interests
in the Warrants (if any) they held on the date of the change of
control.
If the Resolutions are not passed on or before 7 August 2020, a
holder of the Warrants may elect to convert its Warrants without
payment into Tranche 3 Notes with a principal amount equal to the
aggregate exercise price of those Warrants, in compensation for the
right to exercise those Warrants not having arisen.
Until the Resolutions have been passed, no Loan Notes are
capable of conversion. If the Resolutions are passed on or before 7
August 2020, the Tranche 1 Notes will automatically convert into
Ordinary Shares, save that no new Ordinary Shares will be issued
which would result in any person holding in excess of 9.99% of the
aggregate voting rights in the Company as a result of the relevant
conversion.
After the Resolutions have been passed, those Tranche 1 Notes
not automatically converted and any Tranche 2 Notes will be
convertible into Ordinary Shares at the election of the Noteholders
at any time prior to their maturity date, and subject to the 9.99%
beneficial ownership limit. The Tranche 3 Notes are not capable of
conversion.
The Loan Notes are required to be repaid on the earlier of (i)
the applicable maturity date; and (ii) a change of control taking
place in respect of the Company, and are otherwise not able to be
prepaid other than with the consent of a noteholder majority.
The Loan Notes are subject to customary events of default (for
example, insolvency events in respect of the Company and default
under the Company's material contracts, amongst others) and any
principal amount and interest outstanding is capable of being
accelerated following the occurrence of such an event of default
and the expiry of any cure periods applicable thereto.
Details of the Warrants
All the participants in the Fundraising have received
conditional warrants to subscribe for further Ordinary Shares in an
aggregate number equal to 50 per cent of both the new Ordinary
Shares purchased in the Placing and the Ordinary Shares issuable
upon conversion of the Convertible Loan Notes. A total of
161,048,366 Warrants have been issued.
The Warrants have an exercise price of 34.8 pence, which is
equal to 200% of the Issue Price, and will be capable of being
exercised at any time from and after the date the Resolutions are
passed at the General Meeting (or at any subsequent general
meeting) until the third anniversary of the date the Resolutions
are passed. The Warrants can be exercised for cash or on a cashless
basis.
If the Resolutions are not passed at the General Meeting (or at
any subsequent general meeting), the Warrants remain
non-exercisable but will, until 8 August 2025, continue to benefit
from rights to participate in certain transactions. These include
if the Company is acquired, following which the Company is required
to use its best efforts to ensure that Warrant holders receive
alternate warrants in the acquirer. In certain circumstances,
Warrant holders may require the Company (or the acquirer) pay them
(to the extent lawful) the value of the Warrants, determined in
accordance with a Black-Scholes valuation provision.
The Warrant exercise price and the number of shares issuable
upon exercise of the Warrants will be adjusted in certain
circumstances, including if the Company effects a subdivision or
consolidation of its Ordinary Shares, declares a dividend or
distribution, or there is a reorganisation of its Ordinary
Shares.
Registration Rights Agreement
Pursuant to the Securities Purchase Agreement, the Company has
entered into a registration rights agreement (the "Registration
Rights Agreement") with investors, under which the Company agreed
to register the Placing Shares for resale, together with those
Ordinary Shares issuable by the Company on the exercise of the
Warrants and conversion of the Tranche 1 Notes, under the
Securities Act of 1933, as amended (the "Securities Act"). Pursuant
to the Registration Rights Agreement, the Company will prepare and
file a registration statement with the Securities and Exchange
Commission within 30 days of the Fundraising closing date (the
"Filing Deadline") and has agreed to use commercially reasonable
efforts to have the registration statement declared effective as
soon as practicable, but in any event, no later than 45 days after
the Filing Deadline, or 75 days if the registration statement is
subject to a full review by the Securities and Exchange Commission.
If the Company is unable to meet its obligations to have the
registration statement declared effective or to maintain the
effectiveness of the registration statement for specified time
periods, the Company will be obligated to pay certain liquidated
damages to investors. In addition, subject to certain limitations,
the investors will have piggy-back registration rights under the
Securities Act for the sale of the Company's securities for its own
account or for the account of any of its shareholders.
Circular and Notice of General Meeting
The Company expects to publish a circular (the "Circular") in
due course in connection with the Fundraising, which will contain a
notice convening the General Meeting.
Unregistered Shares
The securities sold in the Fundraising have not been registered
under the Securities Act of 1933, as amended, or any state or other
applicable jurisdiction's securities laws, and may not be offered
or sold in the United States absent registration or an applicable
exemption from the registration requirements of the Securities Act
and applicable state or other jurisdictions' securities laws. The
Company has agreed to file a registration statement with the U.S.
Securities and Exchange Commission (the "SEC") registering the
resale of the Placing Shares and the new Ordinary Shares issuable
upon conversion of the Convertible Loan Notes and the Ordinary
Shares issuable upon the exercise of the Warrants no later than the
45th day after the closing of the Fundraising.
Non-Solicitation
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the Placing Shares, the new
Ordinary Shares issuable upon conversion of the Convertible Loan
Notes and the Ordinary Shares issuable upon the exercise of the
Warrants, nor shall there be any offer, solicitation or sale of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful. Any offering of the
securities under the resale registration statement will only be
made by means of a prospectus.
Additional Information
The person responsible for arranging the release of this
information on behalf of the Company is Charles Sermon, General
Counsel.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Adviser
and Broker to Mereo ) +44 (0)20 7894 7000
Phil Davies
Will Goode
Burns McClellan (US Public Relations Adviser
to Mereo) +01 (0) 212 213 0006
Lisa Burns
Steve Klass
FTI Consulting (UK Public Relations Adviser
to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
DEFINITIONS
The following definitions apply throughout this Announcement,
unless the context requires otherwise.
"Admission" admission of the Placing Shares to trading
on AIM, in accordance with Rule 6 of the AIM
Rules;
"AIM" a market operated by London Stock Exchange;
"AIM Rules" the AIM Rules for Companies as published by
London Stock Exchange from time to time;
"Announcement" this announcement;
"Board" or "Directors" the board of directors of the Company;
"Circular" the circular expected to be published in due
course in connection with the F undraising
and containing notice of the General Meeting;
"Company" or "Mereo" Mereo BioPharma Group plc, a company incorporated
in England & Wales and with registered number
9 481161 ;
"Convertible Loan Notes" $50.6 million (GBP40.5 million) GBP 1 convertible
loan notes issued as part of the Fundraising
"Existing Ordinary Shares" the 124,507,857 Ordinary Shares in issue at
the date of this Announcement;
"FCA" the Financial Conduct Authority;
"Fundraising" the issue of the Placing Shares and the Convertible
Loan Notes
"General Meeting" the general meeting of the Company to be convened
in due course;
"Group" the Company and its subsidiary undertakings;
" Issue Price " 17.4 pence per new Ordinary Share;
" London Stock Exchange London Stock Exchange plc;
"
"MAR" Market Abuse Regulation (596/2014);
"Notice of General Meeting" the notice of the General Meeting to be set
out at the end of the Circular;
"Ordinary Shares" ordinary shares of GBP0.003 each in the capital
of the Company;
"Placing" the placing of the Placing Shares at the Issue
Price;
"Placing Shares" 8 9,144,630 new Ordinary Shares which are
to be placed pursuant to the Placing;
"Resolutions" the resolutions to be proposed at the General
Meeting, details of which are to be set out
in the notice of General Meeting;
"Shareholders" holders of Ordinary Shares; and
"Warrants" the 1 61.0 million conditional warrants to
subscribe for 1 61.0 million new Ordinary
Shares at a price of 3 4.8 pence per new Ordinary
Share
Exchange Rate: GBP1:$1.249
KEY STATISTICS
Number of Placing Shares 89,144,630
Ordinary Shares in issue following the issue of the
Placing Shares(1) 213,652,487
Proceeds of the Fundraising (before expenses) $70 million (GBP56
million)
Principal amount of Convertible Loan Notes issued $50.6 million (GBP40.5
million)
Number of Ordinary Shares resulting from full conversion
of Convertible Loan Notes(2) 232,952,121
Number of Ordinary Shares resulting from full exercise
of Warrants 161,048,366
Proceeds of full exercise of Warrants(3) $70 million (GBP56
million)
Aggregate number of Fundraising shares(4) 483,145,117
Maximum percentage of enlarged Ordinary Share capital
represented by the New Fundraising(5) 79.5%
Notes
(1) As at June 2, 2020, being the latest practicable date prior
to the publication of this Document.
(2) Assumes conversion of entire principal amount of Convertible
Loan Notes (but not interest).
(3) Assumes exercise of all Warrants at GBP0.348 per new
Ordinary Share with no cashless exercise
(4) Being the Placing Shares, the new Ordinary Shares resulting
from conversion of the Convertible Loan Notes and the Ordinary
Shares resulting from exercise of the Warrants, assuming the
resolutions are passed, conversion of the entire principal amount
of Convertible Loan Notes (but not interest) and exercise of all
Warrants.
(5) Assumes conversion of the entire principal amount of
Convertible Loan Notes (but not interest) and exercise of all
Warrants, and there is no further issue of shares between Admission
and the date of exercise of all the Warrants. The percentage of the
enlarged share capital represented by the Ordinary Shares resulting
from the exercise of the Warrants will be lower than the maximum
number referred to above to the extent that the Company issues
additional Ordinary Shares in the future.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the United
States Securities Exchange Act of 1934, as amended (the "Exchange
Act"). Forward-looking statements usually relate to future events
and anticipated revenues, earnings, cash flows or other aspects of
our operations or operating results. Forward-looking statements are
often identified by the words "believe," "expect," "anticipate,"
"plan," "intend," "foresee," "should," "would," "could," "may,"
"estimate," "outlook" and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties (some of which are significant
or beyond its control) and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company's business, including those described in its Annual
Report on Form 20-F, Reports on Form 6-K and other documents filed
from time to time by the Company with the United States Securities
and Exchange Commission (the "SEC") and those described in other
documents the Company may publish from time to time should be
carefully considered. The Company wishes to caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo's shareholders will be able to obtain a copy of the
Circular (when available) from the Company's website at
www.mereobiopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSMSILESSELM
(END) Dow Jones Newswires
June 04, 2020 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 12 2024 まで 1 2025
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 1 2024 まで 1 2025
